GlassScriptPhysician profile
Yu-Hsiang S Lee
NPI 1245262013
$19,279.11
in general payments reported to CMS, 2019-2025
35 companies · $2,826 in 2025
The $2,826 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,261 · 2020: $1,206 · 2021: $2,024 · 2022: $3,237 · 2023: $3,473 · 2024: $5,252 · 2025: $2,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $1,245 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,294.27 |
| Travel and Lodging | $1,245.19 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,459.43 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Merz North America, INC. | $2,375.18 | 2024 | |
| Amgen INC. | $2,308.01 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $1,643.97 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,391.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,374.61 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,358.91 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novo Nordisk INC | $1,251.94 | 2020-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $682.98 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $623.88 | 2021-2025 | |
| Amarin Pharma, INC. | $587.82 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $567.59 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $376.26 | 2021-2023 | |
| Vivus LLC | $325.59 | 2022-2025 | Pancreaze |
| Aimmune Therapeutics, INC. | $205.28 | 2024-2025 | Zenpep |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $182.68 | 2021-2022 | |
| Exact Sciences Corporation | $176.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $172.13 | 2019-2025 | Zoryve |
| Allergan, INC. | $169.71 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $145.78 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.62 | 2024-2025 | Xifaxan, Trulance |
| Pfizer INC. | $138.46 | 2023-2025 | |
| Corium, LLC | $123.91 | 2022-2023 | Adlarity |
| Eisai INC. | $98.77 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $90.29 | 2021-2023 | Belsomra |
| Redhill Biopharma INC. | $63.99 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $51.21 | 2021 | |
| Radius Health, INC. | $48.00 | 2024-2025 | Tymlos |
| Sanofi Pasteur INC. | $38.98 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $23.81 | 2023 | Quviviq |
| Exeltis, USA INC. | $20.49 | 2025 | Slynd |
| Sun Pharmaceutical Industries INC. | $19.78 | 2021 | |
| Electromed, INC. | $18.86 | 2024 | Smartvest |
| Biogen, INC. | $18.62 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu-Hsiang Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.